# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2011 Earnings Results

**Report date:** 2012-02-13 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2011

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 12.31%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | +41.08% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future growth. They emphasized their commitment to innovation despite current challenges.

**Key quotes:**

> Management highlighted ongoing research and development efforts.

> They expressed confidence in future product pipelines.

### Guidance Changes

No guidance data was provided during the earnings call.

### What It Means

Regeneron's earnings report shows a significant surprise in EPS, which contributed to a strong stock reaction, rising 12.31%. Investors may be encouraged by the positive EPS surprise, indicating better-than-expected performance despite the lack of revenue data. The management's focus on R&D suggests a commitment to future growth, which could further bolster investor confidence.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2011_